Inactive Instrument

Ajanta Pharma Ltd Stock NSE India S.E.

Equities

INE031B01031

Pharmaceuticals

End-of-day quote NSE India S.E.
- INR - Intraday chart for Ajanta Pharma Ltd
Sales 2024 * 42.01B 504M Sales 2025 * 47.09B 565M Capitalization 276B 3.31B
Net income 2024 * 8.08B 96.94M Net income 2025 * 9.5B 114M EV / Sales 2024 * 6.39 x
Net cash position 2024 * 7.97B 95.63M Net cash position 2025 * 13.8B 166M EV / Sales 2025 * 5.57 x
P/E ratio 2024 *
34.6 x
P/E ratio 2025 *
29.2 x
Employees -
Yield 2024 *
0.92%
Yield 2025 *
0.76%
Free-Float 50.31%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 48 98-12-31
Chief Executive Officer 52 95-12-31
Director of Finance/CFO 59 98-04-22
Members of the board TitleAgeSince
Chief Executive Officer 52 95-12-31
Chairman 77 79-12-30
Director/Board Member 78 08-10-19
More insiders
Ajanta Pharma Limited is an India-based specialty pharmaceutical company. The Company provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. The Company is engaged in the manufacturing and sale of branded generic and generic pharmaceutical products. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its branded generics business is spread across India, the rest of Asia, and Africa. Its business also consists of two verticals: United States generics and institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). The Company's cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin.
More about the company